Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2016 - 2025)

Historic Preferred Stock Liabilities for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q4 2025 value amounting to $1.3 million.

  • Enanta Pharmaceuticals' Preferred Stock Liabilities fell 288.89% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 288.89%. This contributed to the annual value of $1.3 million for FY2025, which is 288.89% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Preferred Stock Liabilities is $1.3 million, which was down 288.89% from $1.3 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $1.5 million for Q3 2021, and its period low was $1.3 million during Q3 2025.
  • Its 5-year average for Preferred Stock Liabilities is $1.4 million, with a median of $1.4 million in 2022.
  • The largest annual percentage gain for Enanta Pharmaceuticals' Preferred Stock Liabilities in the last 5 years was 182.56% (2021), contrasted with its biggest fall of 915.23% (2021).
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Preferred Stock Liabilities stood at $1.5 million in 2021, then dropped by 5.51% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then decreased by 5.13% to $1.3 million in 2024, then decreased by 2.89% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q4 2025, $1.3 million for Q3 2025, and $1.3 million during Q2 2025.